Mansouri Yasaman, Guttman-Yassky Emma
Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY 10029, USA.
J Clin Med. 2015 Apr 29;4(5):858-73. doi: 10.3390/jcm4050858.
Atopic dermatitis (AD) is the most common inflammatory skin disease. Recent research findings have provided an insight into the complex pathogenic mechanisms involved in this disease. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are still lacking. Biomarkers of lesional, nonlesional skin, and blood have been developed for baseline as well as after treatment with broad and specific treatments (i.e., cyclosporine A and dupilumab). These biomarkers will help with the development of novel targeted therapeutics and assessment of disease reversal, with the promise of a more personalized treatment approach. Since AD involves more than one subtype (i.e., intrinsic/extrinsic, pediatric/adult, etc.), these molecular fingerprints needs to be validated in all subpopulations with AD.
特应性皮炎（AD）是最常见的炎症性皮肤病。最近的研究结果为该疾病所涉及的复杂致病机制提供了深入了解。尽管患病率不断上升，但中度至重度AD患者仍缺乏有效且安全的治疗方法。针对皮损、非皮损皮肤和血液的生物标志物已被开发出来，用于基线以及使用广泛和特定治疗（即环孢素A和度普利尤单抗）治疗后的情况。这些生物标志物将有助于开发新型靶向治疗方法并评估疾病逆转情况，有望实现更个性化的治疗方法。由于AD涉及不止一种亚型（即内源性/外源性、儿童/成人等），这些分子指纹需要在所有AD亚群中得到验证。
